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Andrew R. Castle and Andrew C. Gill *
Neurobiology Division, The Roslin Institute and Royal (Dick) School of Veterinary Sciences, University of Edinburgh,
Edinburgh, UK
The prion protein, PrPC, is a small, cell-surface glycoprotein notable primarily for its
critical role in pathogenesis of the neurodegenerative disorders known as prion diseases.
A hallmark of prion diseases is the conversion of PrPC into an abnormally folded
isoform, which provides a template for further pathogenic conversion of PrPC, allowing
disease to spread from cell to cell and, in some circumstances, to transfer to a new
host. In addition to the putative neurotoxicity caused by the misfolded form(s), loss of
normal PrPC function could be an integral part of the neurodegenerative processes and,
consequently, significant research efforts have been directed toward determining the
physiological functions of PrPC. In this review, we first summarise important aspects of
the biochemistry of PrPC before moving on to address the current understanding of the
various proposed functions of the protein, including details of the underlying molecular
mechanisms potentially involved in these functions. Over years of study, PrPC has been
associated with a wide array of different cellular processes and many interacting partners
have been suggested. However, recent studies have cast doubt on the previously
well-established links between PrPC and processes such as stress-protection, copper
homeostasis and neuronal excitability. Instead, the functions best-supported by the
current literature include regulation of myelin maintenance and of processes linked to
cellular differentiation, including proliferation, adhesion, and control of cell morphology.
Intriguing connections have also been made between PrPC and the modulation of
circadian rhythm, glucose homeostasis, immune function and cellular iron uptake, all
of which warrant further investigation.
Keywords: prion, PrPC, transmissible spongiform encephalopathies, differentiation, adhesion, proliferation,
myelin maintenance, stress protection
THE CELLULAR PRION PROTEIN AND ITS GENE
The cell surface glycoprotein known as the cellular prion protein (PrPC) has been the subject
of intensive study since it was first proposed that misfolding of PrPC plays a key role in
the pathogenesis of the neurodegenerative disorders referred to as either the transmissible
spongiform encephalopathies (TSEs) or prion diseases (Prusiner, 1982). Rather than focusing on
the involvement of prion protein in disease, this review provides an overview of the physiological
function of PrPC as it is currently understood. However, before addressing PrPC function, we first
introduce some important aspects of the biochemistry/molecular biology of PrPC and its gene
(PRNP) that are of functional relevance, starting with an exploration of the evolutionary history
of PRNP.
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Prion Genes and Their Evolutionary History
PrPC is encoded by the PRNP gene located on chromosome 20
(in humans—in mice this is chromosome 2) and is remarkably
conserved throughout vertebrates. In addition to PRNP, the
mammalian prion gene family includes SPRN, which encodes a
protein referred to as shadoo (Sho), and PRND, which encodes
a protein known as doppel (Dpl). Sho and Dpl share structural
similarities to PrPC (see below and Figure 2) and several theories
have been put forward to explain the development of this gene
family over evolutionary time. Three such theories are outlined in
diagrammatic form in Figure 1. Figure 1A shows an explanation
proposed by Schmitt-Ulms et al. (2009) and developed in other,
more recent publications (Ehsani et al., 2011, 2012). The authors
of these papers provided evidence that the prion gene family is
evolutionarily descended from the LIV-1 branch of the ZIP (Zrt- ,
Irt-like) metal ion transporter family. Specifically, Ehsani et al.
(2011) suggested that the ancestral PRNP gene could have been
created as a result of reverse transcription of the mRNA of a ZIP
gene, followed by insertion into the genome at a new position, a
process known as retroposition. This event is proposed to have
occurred around the time of the first vertebrates, which would
explain the presence of PRNP homologs in all vertebrate lineages.
In this model, a subsequent gene duplication event, in addition to
some form of genomic rearrangement, led to modern-day SPRN,
which is situated on chromosome 10 in the human genome. A
FIGURE 1 | Theories of the evolutionary history of the prion gene family. The figure shows three possibilities for the evolution of the mammalian prion gene
family. (A) Schmitt-Ulms et al. (2009) proposed that an ancestral PRNP gene evolved from a member of the ZIP metal ion transporter family. Subsequently, this PRNP
precursor gave rise to the modern-day prion gene family through local duplications and other genomic rearrangements. (B) This alternative version, also put forward
by Schmitt-Ulms et al. (2009), incorporates additional research by Premzl et al. (2004) suggesting that SPRN existed before PRNP and that the genetic material
encoding the N-terminal domain of an ancestral PrPC evolved from a gene called SPRNB1 that, itself, had emerged from the original SPRN. The genetic material
encoding the C-terminal domain of the ancestral PrPC is proposed to have derived from a ZIP gene and a later, local duplication would have then created modern-day
PRNP and PRND. Although, descendants of SPRNB2 are found in fish, this gene is thought either to have been deleted or to have evolved beyond detectability in the
mammalian lineage (Premzl et al., 2004). (C) A further possibility is that ancestral PRNP and SRPN genes could have evolved out of ZIP genes in separate events
(Westaway et al., 2011).
later, local duplication would have then given rise to modern-
day PRNP and PRND, which are directly adjacent to one another
in the genome (Westaway et al., 2011). Figure 1B displays an
alternative scenario also outlined by Schmitt-Ulms et al. (2009)
but incorporating earlier research suggesting that SPRN may be
evolutionarily more ancient than PRNP (Premzl et al., 2004).
As per the first theory, the genetic material encoding the PrPC
C-terminal domain could have originated from an ancestral
ZIP gene. Contrastingly, the sequences encoding the N-terminal
domain may have arisen from a pre-existing SPRN-like gene
(SPRNB1) that was created by earlier duplications of an SPRN
founder gene. The generation of intergenic mRNA transcripts
or an alternative form of local rearrangement could have caused
these sequences to merge to form the ancestral PRNP (Westaway
et al., 2011). A third model (Figure 1C) is that ancestral PRNP
and SRPN genes could have evolved out of ZIP genes in separate
events (Westaway et al., 2011).
Regulation of PRNP Expression
Although PRNP has a short GC-rich region immediately
upstream of its transcription start site, as well as other features
common to housekeeping genes (Puckett et al., 1991; Sakudo
et al., 2010), intron 1 and the sequences upstream of the
transcription start site also contain evolutionarily conserved,
putative binding sites for numerous transcription factors,
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including Sp1 (Basler et al., 1986), activator proteins 1 and 2
(Mahal et al., 2001), forkhead box protein O3 (Liu et al., 2013),
regulatory factor X1, heat shock factor 2, GATA-binding factor
3, thyrotrophic embryonic factor, myocyte enhancer factor 2,
ecotropic viral integration site 1, E4 promoter-binding protein, 4
and nuclear matrix protein 4/cas-interacting zinc finger protein
(Kim et al., 2008). These regulatory sequences presumably enable
dynamic control of PrPC expression in response to various
stimuli, for example, treatment of cultured cells with nerve
growth factor, insulin or insulin-like growth factor induces PrPC
expression (Kuwahara et al., 2000; Zawlik et al., 2006; Liu et al.,
2013). Additionally, endoplasmic reticulum (ER) stress, oxidative
stress and genotoxic stress are all reported to cause upregulation
of PrPC expression (Dery et al., 2013; Cichon and Brown, 2014;
Bravard et al., 2015).
Structure and Basic Intracellular
Trafficking of PrPC
PrPC is synthesised as a precursor protein of 253 amino
acids (human numbering) with an N-terminal signal peptide
that codes for entry into the ER. However, seemingly because
of an inefficiency in this ER-targeting signal (Rane et al.,
2004), a small percentage of precursor molecules may fail to
translocate fully into the ER lumen. Some of this PrPC is
consequently retained in the cytoplasm. Interestingly, the levels
of this immature, non-translocated PrPC may be upregulated
by ER stress (Orsi et al., 2006). Another form, known as
CtmPrP, partially enters the ER—the hydrophobic domain of
PrPC (see below) acts as a transmembrane domain, leaving
the C-terminal region within the ER lumen and the N-
terminal region in the cytoplasm. Reports suggest that CtmPrP
is retained either in the ER or the Golgi apparatus before
eventual degradation by the proteasome (Stewart et al., 2001,
2005). A second transmembrane form of PrPC called NtmPrP
can be produced if the molecule inserts into the ER membrane
in the opposite orientation to CtmPrP. However, NtmPrP
has rarely been studied in any detail (Chakrabarti et al.,
2009). These forms appear more related to disease than
physiological PrPC function and are not considered further
here.
The vast majority of immature PrPC molecules translocate
properly into the ER, enabling cleavage of a C-terminal
signal peptide and addition of a glycophosphatidylinositol
(GPI) anchor. Removal of both signal sequences results in
a mature protein of 208 amino acids (residues 23–230 of
the precursor protein), the structure of which is shown in
Figure 2. The N-terminal domain is traditionally viewed as
intrinsically disordered, but may possess elements of stable
structure (Gill et al., 2000; Blanch et al., 2004; Taubner et al.,
2010) that could enable PrPC to interact with multiple partners
(Bakkebo et al., 2015). The N-terminal domain also contains
four tandem repeats of a sequence of eight amino acids, a
region of PrPC that is missing in Dpl. These octapeptide
repeats may be functionally significant since analysis of PrPC
sequences from 53 species showed excellent conservation (Kim
et al., 2008). A hydrophobic section (approximately residues
112–133) spans the divide between the N- and C-terminal
domains and may be involved in PrPC dimerisation (Rambold
et al., 2008; Beland and Roucou, 2013). The PrPC C-terminal
domain has a globular structure, consisting of three α-helices,
two β-strands and interconnecting loops (Riek et al., 1996; Haire
et al., 2004). There is also a disulphide bond between residues
179 and 214 (Zahn et al., 2000) and N-linked glycans can
be added at residues 181 and 197—the vast majority of PrPC
is generally thought to be di-glycosylated, although this may
not be the case in all tissue/cell types (Williams et al., 2004).
Notably, the entire globular domain is missing in Sho, but this
protein does possess degenerate peptide repeats in theN-terminal
region.
After passing through the ER, PrPC moves to the Golgi
apparatus where the N-linked glycans mature and the protein
is sorted for trafficking to the cell surface. Once there, the
GPI anchor attaches PrPC to the extra-cytoplasmic face of
the cell membrane, specifically in microdomains called lipid
rafts (Vey et al., 1996). Dpl and Sho also both have GPI
anchors and are therefore similarly targeted to the cell surface
(Silverman et al., 2000; Watts et al., 2007). Interestingly, not
all PrPC is found at the cell surface. The protein seems to
be subject to cycles of internalisation followed by trafficking
back to the cell membrane via recycling endosomes (Shyng
et al., 1993; Magalhaes et al., 2002; Sunyach et al., 2003), a
process that presumably exists to enable tight control of the
cell surface pool of PrPC. Studies using a green fluorescent
protein reporter system have suggested that this recycling process
may also result in PrPC expression within the Golgi apparatus
(Lee et al., 2001; Magalhaes et al., 2002; Nikles et al., 2008).
Furthermore, there are reports that PrPC can be present in
the nucleus (Gu et al., 2003; Morel et al., 2008; Besnier et al.,
2015; Bravard et al., 2015) and in mitochondria (Hachiya et al.,
2005; Satoh et al., 2005; Sorice et al., 2012; Faris et al., 2017).
Regardless of the different subcellular locations that PrPC can
reside, the functional form is believed to be that present on the
cell surface.
Spatiotemporal Distribution of PrPC
Expression
PrPC is most highly expressed in the central nervous system
(CNS) although PRNP transcripts can also be found in many
other tissue/cell types, albeit at somewhat lower levels. Publically
available PRNP expression data from microarray analyses of
various human tissues and cell types (Su et al., 2004) are shown in
Figure 3 in the form of a bar chart for purposes of comparison. By
contrast, in the same microarray dataset SPRN transcripts were
found to be restricted to CNS and peripheral nervous system
(PNS) tissues, whilst PRND expression was confined largely to
the testes. At the protein level, PrPC expression in the brain
appears to increase throughout development, reaching a peak
in early life before reducing somewhat toward adulthood (Sales
et al., 2002; Adle-Biassette et al., 2006). It is unclear how PrPC
levels in the brain are affected by the ageing process—one study
found increased PrPC expression in the brains of aged mice
(Williams et al., 2004), whilst analysis of post-mortem human
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FIGURE 2 | Structural features of PrPC. (A) Ribbon diagram of the PrPC molecule. The C-terminal domain contains three α-helices, shown in red and yellow, and
two β-strands shown in turquoise, whereas the N-terminal domain has been added on in a “random” configuration. (B) Schematic representation of PrPC, Sho, and
Dpl to highlight key structural features in greater detail. PrPC possesses octa-peptide repeats in the N-terminal region, whilst shadoo has two different, imperfect
repeat stretches. SIG, N- and C-terminal signal peptides; HR, hydrophobic region.
brain tissues showed that PrPC expression in the hippocampus
was significantly reduced in older individuals (Whitehouse et al.,
2010).
Most reports indicate that PrPC is expressed not only in
neurons but also in astrocytes (Lima et al., 2007; Hartmann et al.,
2013), oligodendrocytes (Moser et al., 1995; Bribian et al., 2012),
and microglia (Adle-Biassette et al., 2006), although one study
found that PrPC expression was inhibited both in vitro and in
vivo following differentiation of neural precursors into glial cell
types (Steele et al., 2006). Non-neural cells of the forebrain also
stain for PrPC, including the endothelial cells in blood vessel walls
(Adle-Biassette et al., 2006). Furthermore, PrPC expression has
been reported in the PNS, including the dorsal and ventral root
ganglia of the spinal cord (Tremblay et al., 2007; Peralta et al.,
2012; Ganley et al., 2015), sensory and motor axons (Manson
et al., 1992) and Schwann cells (Follet et al., 2002). Outside of the
nervous system, PrPC expression has been detected in immune
cells, including T-lymphocytes, natural killer cells and mast cells
(Durig et al., 2000; Haddon et al., 2009), and also in multiple
organs, including the heart, pancreas, intestine, spleen, liver, and
kidneys (Peralta and Eyestone, 2009).
Proteolytic Processing of PrPC
So far in this review, PrPC has been referred to as a single entity.
However, as summarised in Figure 4, PrPC can be proteolytically
processed in several ways. Firstly, PrPC can be enzymatically
cleaved at the peptidyl bond between residues 110 and 111
(human numbering) that lies just outside the hydrophobic
domain of the protein (Chen et al., 1995; Watt et al., 2005).
A recent study proposed that this “α” form of cleavage may
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FIGURE 3 | Expression levels of PRNP in various human tissues and cell types. The data for this chart originate from a publically available microarray dataset
(GeneAtlas U133A, probeset 201300_s) originally published by Su et al. (2004) that was accessed through the BioGPS gene annotation portal (Wu et al., 2016). The
bars on the chart indicate the arithmetic mean fluorescence signals from the replicate analytes; the error bars show standard error of the mean.
also occur at alternative sites within the hydrophobic domain
itself (McDonald et al., 2014). Members of the disintegrin and
metalloproteinase domain-containing protein (ADAM) family
may be responsible for α-cleavage (Vincent et al., 2001; Cisse
et al., 2008; McDonald et al., 2014), although not all studies
support this idea (Beland et al., 2012;Wik et al., 2012). α-Cleavage
is thought to occur either in an acidic endosomal compartment
(Shyng et al., 1993) or within the Golgi apparatus (Walmsley
et al., 2009) and results in the production of the N-terminal
fragment N1, which is released from the cell, and the C-terminal
fragment C1, which seems to be trafficked to the cell membrane
as per the full length protein (Harris et al., 1993; Vincent et al.,
2000; Laffont-Proust et al., 2006). A large proportion of the
cellular pool of PrP molecules may be in the form of C1—
around 50% on average in sheep cerebral cortex, for example
(Campbell et al., 2013). In addition to the α form of processing,
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FIGURE 4 | Proteolytic processing of PrPC. Post-translational and proteolytic processing events create multiple distinct PrP fragments. Ribosomal expression of
PrPC is concomitant with ER translocation. Imperfect translocation can result in NtmPrP or CtmPrP. Once in the ER, the immature protein (1) is N- and C-terminally
truncated, glycosylated, the membrane anchor is added and the single disulphide bond is formed to produce the mature protein (2), before (potentially
chaperone-mediated) folding to produce the folded form (3). Enzymatic α-cleavage, possibly mediated by ADAM family proteases, results in the production of N1 and
C1 and is thought to occur either in an acidic endosomal compartment or within the Golgi apparatus. These fragments and the remaining, uncleaved PrPC molecules
are trafficked to the cell surface. Once there, PrPC can be subject to β-cleavage, possibly stimulated by the combined presence of ROS and Cu2+, leading to the
production of N2 and C2. ADAM protease-mediated shedding may also occur, which results in cleavage of PrPC near its GPI anchor, thereby producing the N3
fragment. The sites of proteolytic cleavage are shown schematically in Figure 2B.
PrPC can be subject to cleavage within its octapeptide repeat
region (McMahon et al., 2001). Recent findings from cell-free
experiments using recombinant PrP suggest that this “β” cleavage
can occur between the adjacent His and Gly residues of each
octapeptide sequence (residues 61/62, 69/70, 77/78, and 85/86
for human PrPC) (McDonald et al., 2014). Whilst cleavage was
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equally likely at each site, the authors of this study caution that
the presence of PrPC binding partners may cause a particular
site to be favoured in vivo. β-Cleavage seems to be dependent
upon the combined presence of Cu2+ and reactive oxygen species
(ROS) (McMahon et al., 2001), although enzymatic processing
by ADAM8 is also a possibility (McDonald et al., 2014). The
apparent role for ROS in β-cleavage suggests that it might be
a response to oxidative stress (Watt et al., 2005), although β-
cleavage also seems to occur physiologically, since the resulting
C-terminal fragment, C2, is found in healthy brain tissues from
various species, albeit in small amounts (Mange et al., 2004;
Campbell et al., 2013). β-Cleavage is thought to take place at the
cell surface, leading to retainment of C2 on the cell membrane
and release of the N-terminal fragment N2 (Mange et al., 2004;
Watt et al., 2005). In a third form of PrPC processing, referred to
as “shedding,” the protein can be cleaved at the 227/228 peptidyl
bond (mouse numbering) by ADAM10, which removes the GPI
anchor and the three adjacent amino acid residues, allowing
the remaining protein fragment, sometimes known as N3, to
be released into the extracellular medium (Taylor et al., 2009;
McDonald et al., 2014).
Why Should We Care about Cellular Prion
Protein Function?
Before turning to PrPC function, some introductory comments
on the diseases that made the prion protein notorious are
warranted, since the role that this protein plays in these
diseases drives the abundance of studies into its function.
Prion diseases are infectious diseases characterised by long,
pre-clinical incubation periods followed by rapidly progressing
neurodegeneration. Although rare, prion diseases are uniformly
fatal and many mammalian species are susceptible (Fernandez-
Borges et al., 2012). Animal prion diseases include scrapie in
sheep and goats, bovine spongiform encephalopathy in cattle
and goats, and chronic wasting disease in deer, whilst sporadic
Creutzfeldt-Jakob disease is the most common human prion
disease (Head, 2013). Early studies of the infectious agent
suggested that it was too small and too resistant to UV irradiation
to contain any living organism, even a virus (Alper et al., 1966,
1978; Alper, 1985). Subsequently, a protein was isolated from
prion-infected hamster brains and its concentration appeared
to be proportional to prion infectivity (Prusiner et al., 1982;
McKinley et al., 1983). This discovery led to the prion hypothesis,
which proposes that the novel protein is the major component
of the infectious agent of all prion diseases, the term “prion”
deriving from proteinaceous infectious particle (Prusiner, 1982).
The infectious protein was later shown to be a host genome-
encoded protein, now known as PrPC, that can undergo
conversion to a partially protease-resistant, misfolded form
referred to as PrPSc (McKinley et al., 1983; Prusiner et al., 1985;
Horwich and Weissman, 1997). The misfolding process leads to
a reduction in the amount of α-helical structure and an increase
in β-sheet conformation (Pan et al., 1993), which makes PrPSc
prone to aggregation. PrPSc is also thought to act as a template
for further pathogenic conversion of the normally folded form
(Horwich and Weissman, 1997), enabling disease to spread from
cell to cell, from individual to individual and, in rarer instances,
to transfer between species.
In addition to its role in prion disease transmission, PrPSc
is thought to be involved in the disease processes that cause
neuronal cell death, especially when aggregated into soluble
oligomers (Ugalde et al., 2016). The loss of normal PrPC
function may also play a role in the pathogenesis of prion
disease, since data from various animal models indicate that
PrPC levels fall as disease progresses (Mays et al., 2014). Given
the absence of disease-modifying treatments for these diseases,
therapeutic interventions that further reduce PrPC expression
or block its ability to interact with PrPSc are being investigated;
better knowledge of PrPC function would aid risk assessment
of these approaches. Additionally, knowing which proteins
interact with PrPC physiologically might enable the development
of other treatment strategies for prion diseases. Finally, as
described later in this review, some beneficial functions of PrPC
could be exploited independently for therapeutic purposes. For
these reasons, the physiological function of PrPC has been
investigated intensively over recent years and the knowledge
gained from such research will be summarised in the following
sections.
ANIMAL MODELS FOR INVESTIGATING
PRPC FUNCTION
PrPC-Knockout Mice
One way to assess protein function is to analyse the consequences
of ablating expression in animals. As such, several groups
have independently generated lines of PrPC-knockout mice, as
summarised in Table 1. The first PrPC-knockouts were created in
the early 1990s by gene targeting methods; these lines are referred
to as Zurich I (Bueler et al., 1992) and Npu (Manson et al., 1994).
Whilst the lack of PrPC expression completely prevented scrapie
transmission to these mice, thereby providing strong evidence for
the prion hypothesis (Bueler et al., 1993; Prusiner et al., 1993),
no other striking phenotypes were identified in initial analyses
(Bueler et al., 1992; Manson et al., 1994). These results were
surprising given that the structure and amino acid sequence
of PrPC are both well-conserved among mammalian species,
which hints at an important function for the protein (Pastore
TABLE 1 | PrPC-knockout mouse lines.
Knockout line Year of
1st ref.
Genetic
background
Ectopic Dpl? Ataxia?
Zurich I 1992 Mixed No No
Npu 1994 Pure (129/Ola) No No
Zurich III 2016 Pure
(C57BL/6J)
No No
Ki-Prnp-GFP 2008 Mixed Yes (low level) No
Rcm0 1995 Pure (129/Ola) Yes (high level) Yes
Ngsk 1996 Mixed Yes (high level) Yes
Rikn 2001 Mixed Yes (high level) Yes
Zurich II 2001 Mixed Yes (high level) Yes
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and Zagari, 2007). However, more recent studies have identified
several abnormalities of these PrPC-null mice and these findings
will be covered in later sections.
In the years following the generation of the Zurich I and
Npu PrPC-null mice, several groups independently produced
additional knockout lines, known as Rcm0 (Moore et al., 1995),
Ngsk (Sakaguchi et al., 1996), Rikn (Yokoyama et al., 2001),
and Zurich II (Rossi et al., 2001). Unlike the Zurich I and Npu
knockout mice, all the newer lines were shown to develop a
late-onset ataxia due to death of cerebellar Purkinje neurons
(Sakaguchi et al., 1996; Moore et al., 1999; Rossi et al., 2001;
Yokoyama et al., 2001). The reintroduction of PrPC into the
Ngsk line rescued the ataxic phenotype, which seemed to confirm
that it resulted from ablation of PrPC expression (Nishida et al.,
1999). However, the particular gene targeting methods used for
production of the Rcm0, Ngsk, Rikn and Zurich II knockouts
led to the generation of intergenic mRNA transcripts from the
undisrupted, non-protein-coding exons of Prnp and the exons
of the neighbouring Prnd. Therefore, Dpl was being expressed
under the control of the Prnp regulatory sequences, leading to
ectopic Dpl expression in the brains of the PrPC-null mice, but
not the wild type controls (Moore et al., 1999). The presence of
the ataxic phenotype only in knockout mice with ectopic Dpl
expression suggested that the cerebellar Purkinje neurons were
dying from Dpl-mediated neurotoxicity rather than a lack of
PrPC. Further evidence obtained in vitro confirmed that Dpl was
toxic to neuronal cells, but only in the absence of PrPC expression
(Sakudo et al., 2005; Qin et al., 2006). Although, the ability of
PrPC to block the neurotoxic effects of Dpl may derive from a
physical interaction between the proteins (Qin et al., 2006), this
is unlikely to be a genuine physiological function of PrPC in the
brain given that PrPC and Dpl are not typically co-expressed.
The ectopic Dpl expression makes it difficult to interpret the
phenotypes of RcmO, Ngsk, Rikn, and Zurich II PrPC-knockout
mice. A further knockout line (Ki-Prnp-GFP), in which the
protein-coding exon of Prnp was replaced with genetic material
encoding enhanced green fluorescent protein (Heikenwalder
et al., 2008), also exhibit aberrant expression of Prnd transcripts
in the brain but the levels seem low enough not to cause any
overt abnormalities (Jackson et al., 2014). However, one issue
that does affect the Ki-Prnp-GFP line as well as the much
more frequently studied Zurich I line is their mixed genetic
backgrounds. As outlined in a review by Steele et al. (2007), the
result is that the genomes of these PrPC-null mice and their wild
type counterparts may differ at sites other than the Prnp locus.
Importantly, even extensive backcrossing to one of the parental
strains or to a different inbred strain is unlikely to eliminate
this issue completely. This is because alleles of genes linked to
Prnp that derive from the embryonic stem cells used for gene
targeting will tend to persist in the PrPC-knockout line due
to the low probability of recombination between neighbouring
genes (Gerlai, 1996; Nuvolone et al., 2013). Therefore, rather than
resulting from a lack of PrPC expression, some of the phenotypes
of the Zurich I PrPC-null mice may be due instead to the presence
of different alleles of Prnp-linked genes compared with the
wild type controls. Indeed, a specific phenotype associated with
Zurich I (and Ngsk) PrPC-null mice—increased phagocytosis of
apoptotic cells by macrophages—was traced to polymorphisms
in the nearby gene that encodes signal-regulatory protein α-1
(Nuvolone et al., 2013). Due to their pure genetic backgrounds,
the Npu line and a recently derived knockout line called Zurich
III, which has been created using transcription activator-like
effector nuclease genome editing technology (Nuvolone et al.,
2016), are free from the problems caused by interfering linked
genes.
Other Animal Models for Investigating
PrPC Function
Although, mice have been used in the great majority of studies
to investigate PrPC function in vivo, PrPC expression has also
been knocked out in goats and in cattle, both natural hosts of
prion disease. Whilst no in-depth phenotypic description of the
PrPC-null goats has been published, the animals in question
were reported to be healthy up to at least 5 months of age (Yu
et al., 2009; Zhu et al., 2009). Similarly, detailed clinical and
histopathological examinations in addition to analyses of blood
samples and isolated peripheral blood lymphocytes uncovered
no overt abnormalities of PrPC-null cattle (Richt et al., 2007).
However, these observations were made only in relatively young
individuals (up to 20 months of age) and the samples sizes were
small, meaning that subtle phenotypes would have been difficult
to detect.
PrPC function has also been interrogated using zebrafish, in
which three homologs of mammalian PRNP have been identified.
These homologs are known as prp1 and prp2, encoding the
proteins PrP1 and PrP2, respectively, and a more divergent
PRNP-like gene known as prp3, which codes for PrP3 (Cotto
et al., 2005). Conflicting data on the spatiotemporal expression
pattern of PrP1 during embryonic development have been
published (Cotto et al., 2005; Malaga-Trillo et al., 2009). The
evidence is clearer for PrP2 expression, which is reportedly absent
in the early embryo but reaches high levels in the nervous system
during later developmental stages and is maintained following
hatching (Malaga-Trillo et al., 2009; Fleisch et al., 2013).
Knockdown of PrP1 or PrP2 expression using morpholinos
has identified putative roles for both proteins in regulating
cell adhesion (Malaga-Trillo et al., 2009; Huc-Brandt et al.,
2014; Sempou et al., 2016). Furthermore, complete knockout of
PrP2 expression using zinc finger nuclease technology increased
susceptibility to seizures (Fleisch et al., 2013), suggesting that
PrP2 might modulate neuronal excitability. There is some
evidence that mammalian PrPC has similar functions to the
zebrafish PrPs and this will be described in more detail in
subsequent sections.
Recently, the first non-experimental animals without PrPC
expression were identified. Naturally occurring PrPC-null
animals represent a useful resource for studying PrPC function
since they are free from the confounding factors that can be
introduced by genetic manipulation. The animals in question
were goats of the Norwegian Dairy Goat breed that were
homozygous for a Prnp allele with a premature stop codon at
position 32, just a few amino acids after the end of the N-terminal
signal peptide (Benestad et al., 2012). These PrPC-null goats
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appeared to reproduce and behave normally (Benestad et al.,
2012), although it has been reported that theymay have increased
red blood cell and neutrophil counts (Reiten et al., 2015). One
would expect novel insights to arise from these animals in due
course.
PRPC FUNCTION
Significant research efforts have been directed toward
investigating the physiological function of PrPC in various
cellular and animal models. The results from these studies have
suggested roles for PrPC in numerous processes, as will be
explained in the following sections. In order to simplify our
description of PrPC function, we have aimed to group together
putative functions that may be related, including some that may
seem unconnected at first glance but could, in fact, result from
PrPC regulating the same underlying biochemical pathways.
Stress-Protection
The most extensive body of work relating to PrPC function
addresses the putative stress-protective properties of the protein.
Initial evidence came from PrPC protecting neuronal “HpL” cells
from serum withdrawal (Kuwahara et al., 1999)—the loss of
growth and survival factors present in serum results in activation
of mitochondria-dependent apoptotic signalling driven by a
protein called Bax (Deckwerth et al., 1996). Further studies using
HpL cell lines appeared to confirm that PrPC expression confers
protection against serum deprivation-induced apoptosis (Kim
et al., 2004; Wu et al., 2008). However, as described by Kuwahara
et al. (1999), the HpL cell lines were generated by immortalisation
of primary hippocampal neurons derived from embryonic Rikn
PrPC-null mice. As explained previously, Dpl is ectopically
expressed in the brains of these mice; consequently, the HpL cell
lines also express Dpl (Sakudo et al., 2005). Therefore, the greater
susceptibility of HpL cells to serum deprivation compared with
control cell lines derived from wild type mice may have been
caused by the toxic effects of Dpl rather than the absence of
PrPC expression. Additionally, the increased resistance to serum
withdrawal following reintroduction of PrPC into the HpL cells
(Kim et al., 2004; Wu et al., 2008) may merely have been caused
by PrPC interacting with Dpl and inhibiting its neurotoxicity
(Moore et al., 1999; Sakudo et al., 2005; Qin et al., 2006), which, as
previously mentioned, is unlikely to be a physiologically relevant
function of PrPC. More recently, the Zurich I line of PrPC-
knockout mice, which do not have ectopic Dpl expression in the
CNS, was used for the production of additional immortalised
hippocampal cell lines, although there have been conflicting
reports over whether or not PrPC expression confers significant
protection against serum deprivation in these cells (Nishimura
et al., 2007; Oh et al., 2008). Nonetheless, PrPC expression
has been shown to protect human primary neurons and MCF-
7 breast cancer cells from microinjection or transfection with
Bax-expressing constructs (Bounhar et al., 2001; Roucou et al.,
2005). In addition, viability of MDA-MB-435 breast cancer cells
following serum deprivation was reduced by RNA interference-
mediated knockdown of PrPC expression (Yu et al., 2012).
A number of studies have assessed how PrPC affects the
cellular response to staurosporine, a potent but relatively non-
selective adenosine triphosphate-competitive kinase inhibitor
(Ruegg and Burgess, 1989) that seems to induce mitochondria-
independent apoptotic signalling as well as affecting the same
apoptotic pathways activated by serum deprivation (Zhang
et al., 2004). PrPC expression has been reported to protect
primary hippocampal neurons from staurosporine-mediated
cell death, possibly through an interaction with stress-induced
phosphoprotein 1 (STI1) (Lopes et al., 2005; Beraldo et al.,
2010; Ostapchenko et al., 2013). STI1 is a secreted protein
thought to interact with PrPC, leading to activation of the pro-
survival protein kinase A (PKA) signalling pathway (Zanata et al.,
2002; Lopes et al., 2005). Interestingly, studies using primary
cortical neurons derived from Zurich I PrPC-knockout mice
found that transfection with a vector encoding full length PrPC
actually increased susceptibility to staurosporine (Paitel et al.,
2004), whereas the N1 fragment produced by α-cleavage was
neuroprotective (Guillot-Sestier et al., 2009). There are several
additional reports of full length PrPC expression conferring
reduced viability in response to staurosporine exposure in a
number of cell lines (Paitel et al., 2002, 2003; Sunyach et al., 2007;
Guillot-Sestier et al., 2009).
In addition to direct effects on apoptosis, PrPC reportedly
protects cells from oxidative stress. For example, basal levels of
ROS and lipid peroxidation were lower in PrPC-transfected
neuroblastoma and epithelial cell lines compared with
untransfected controls (Rachidi et al., 2003; Zeng et al., 2003).
Moreover, PrPC expression by primary neurons, astrocytes
and cell lines has been associated with lower levels of damage
following exposure to various oxidative toxins (Brown et al.,
1997b, 2002; Anantharam et al., 2008; Dupiereux et al., 2008;
Bertuchi et al., 2012). A possible mechanism is that PrPC
modulates the activities of the antioxidant enzymes that convert
ROS into less toxic products—several studies have shown lower
superoxide dismutase and glutathione peroxidase activities in
the absence of PrPC expression (Brown et al., 1997b; Miele et al.,
2002; Rachidi et al., 2003; Sakudo et al., 2003; Paterson et al.,
2008). Since ROS may induce β-cleavage of PrPC in the presence
of Cu2+, the C2 or N2 fragments could be responsible for the
putative antioxidant properties of PrPC. Indeed, it has been
reported that N2 lowers ROS production in response to serum
deprivation in neuronal cell lines and neural stem cells (NSCs)
(Haigh et al., 2015a,b). As well as potentially increasing the
activities of antioxidant enzymes, a recent study proposed that
PrPC translocates to the nucleus in response to oxidative stress-
induced DNA damage and directly activates the base excision
repair pathway by interacting with AP endonuclease and
enhancing its activity (Bravard et al., 2015). Additionally, PrPC-
mediated activation of the tyrosine-protein kinase Fyn might
lead to a stress-protective release of calcium ions from stores in
the ER (Krebs et al., 2007). However, not all the evidence agrees
with an antioxidant role for PrPC. Other studies have found no
differences in superoxide dismutase activity between PrPC-null
and wild type mice in the spinal cord, spleen or brain (Hutter
et al., 2003; Steinacker et al., 2010). Additionally, although
PrPC protected neuroblastoma cells from the oxidative toxin
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3-morpholinosynonimine hydrochloride through activation
of the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)-
RACα serine/threonine-protein kinase (Akt) signalling pathway,
PrPC transfection actually increased susceptibility to hydrogen
peroxide treatment (Vassallo et al., 2005). Incidentally, PI3K-Akt
signalling can also activate the mammalian target of rapamycin
(mTOR) pathway, leading to reduced levels of autophagy,
thereby rationalising the reported regulation of autophagic flux
by PrPC (Nah et al., 2013; Shin et al., 2014).
Finally, PrPC has been implicated in the response to ER
stress, which is caused by accumulation of unfolded/misfolded
proteins within the ER. A cell responds to ER stress by triggering
the unfolded protein response, which consists of: (1) increased
expression of chaperones to improve protein folding; (2) global
inhibition of protein synthesis; (3) an increase in ER volume; and
(4) activation of the ER-associated protein degradation pathway,
a key pathway in neurodegenerative disorders (Halliday and
Mallucci, 2014). Interestingly, ER stress-response elements have
been found within the human PRNP promoter and they appear
active, since PrPC expression was induced following treatment
of breast carcinoma cells with toxins that cause ER stress (Dery
et al., 2013). In the same study, knockdown of PrPC expression
in several cancer cell lines resulted in increased cell death in
response to these toxins. Higher PrPC expression in spite of the
global, ER stress-induced reduction in protein synthesis suggests
a potential role for PrPC in the unfolded protein response,
although results from other studies argue against a protective role
for PrPC during ER stress (Roucou et al., 2005; Anantharam et al.,
2008).
In conclusion, the idea that PrPC has a direct stress-protective
function remains unproven. For example, there is no clear data
supporting a protective role for PrPC expression in the response
to ER stress and, depending on the cellular context, PrPC
expression is seemingly either pro-survival or pro-apoptotic
following exposure to staurosporine. There is evidence that PrPC
expression protects cells from serum deprivation, although this is
weakened by the use of the Dpl-expressing HpL cells in several of
the relevant studies. Arguably, the evidence that PrPC can protect
cells from oxidative stress is more convincing, although, as far as
we are aware, this putative function has yet to be confirmed in the
genetically pure Npu or Zurich III lines of PrPC-knockout mice.
Cellular Differentiation
In addition to its reported role in neuroprotection, several studies
have shown that PrPC promotes neurite outgrowth, and potential
explanations include interactions of PrPC with STI1 (Lopes et al.,
2005), neural cell adhesion molecule 1 (NCAM1) (Santuccione
et al., 2005), epidermal growth factor receptors (Llorens et al.,
2013), integrins (Loubet et al., 2012), laminin (Graner et al.,
2000a), or metabotropic glutamate receptors (mGluRs) (Beraldo
et al., 2011). The downstream signalling responsible may include
inhibition of the ras homolog gene family, member A (RhoA)-
Rho-associated protein kinase (ROCK) pathway (Loubet et al.,
2012). When activated, this signalling pathway stabilises the actin
cytoskeleton, thereby inhibiting the development of filopodia—
dynamic protrusions from the neurite growth cone that respond
to the extracellular environment to guide migration of the
developing neurite (O’Connor et al., 1990). Activation of the
extracellular signal-regulated kinases 1 and 2 (ERK1/2), PI3K-
Akt, and protein kinase c (PKC) signalling pathways may also be
involved inmediating PrPC-dependent neurite outgrowth (Lopes
et al., 2005; Caetano et al., 2008; Beraldo et al., 2011; Llorens et al.,
2013). It should be cautioned that signal-regulatory protein α-1
reportedly modulates neurite outgrowth (Wang and Pfenninger,
2006) and, as previously mentioned, polymorphisms between
Zurich I PrPC-null mice and their wild type counterparts in
the gene encoding signal-regulatory protein α-1 can be present
even after extensive backcrossing to an inbred strain (Nuvolone
et al., 2016). This confounding factor affects the interpretation of
several studies that used cells derived from these mice to show
apparent regulation of neurite outgrowth by PrPC (Lopes et al.,
2005; Santuccione et al., 2005; Beraldo et al., 2011). However,
investigations of other cell lines are free from this problem and
a connection between PrPC expression and neurite outgrowth
has been demonstrated repeatedly in such models (Graner et al.,
2000a,b; Loubet et al., 2012; Llorens et al., 2013).
Neurite outgrowth is a feature of neuronal differentiation,
which raises the possibility that the effects of PrPC expression
on neurite outgrowth may be consequences of PrPC regulating
differentiation. Indeed, such a role may not be restricted to
the nervous system, since there is evidence that PrPC can
influence some of the earliest differentiation processes that
occur during embryogenesis. For example, PrPC may indirectly
modulate NCAM1 polysialylation in order to regulate the
epithelial-to-mesenchymal transition (Mehrabian et al., 2015,
2016), a vital developmental process that alters cell adhesion
and enables cell migration. Ectodermal cells in the developing
embryo must undergo epithelial-to-mesenchymal transition as
part of gastrulation, which may explain why knockdown of PrP1
expression in zebrafish embryos has been shown to prevent this
process (Malaga-Trillo et al., 2009). This finding suggests that
PrPC may have an evolutionarily-conserved role in regulating
cell adhesion. Indeed, zebrafish PrP1 and PrP2 are reported
to regulate the connections between adherens junctions and
the actin cytoskeleton, mainly by affecting the localisation of
E-cadherin and β-catenin to these junctions (Malaga-Trillo
et al., 2009; Sempou et al., 2016). This process seems to
rely upon signalling through members of the Src family of
tyrosine-protein kinases (Sempou et al., 2016) that could be
mediated by PrP1/2 interacting with the zebrafish NCAM1
ortholog (Santuccione et al., 2005). PrPC has been reported to
regulate other differentiation processes. For example, knocking
down PrPC expression in cultured human embryonic stem
cells delayed spontaneous differentiation into the three germ
layers (Lee and Baskakov, 2013). In a similar manner, PrPC
expression has been shown to promote guided differentiation
of cultured human embryonic stem cells and neural precursors
into neurons, astrocytes and oligodendrocytes (Steele et al., 2006;
Lee and Baskakov, 2014). Furthermore, a role in regulating cell
adhesion suggests that PrPC expression in cancer may affect the
tendency to metastasise. Indeed, Chieng and Say (2015) found
that overexpression of PrPC in a colon adenocarcinoma cell
line increased invasiveness, whilst a study of pancreatic ductal
adenocarcinoma patients reported that PrPC-positive tumours
Frontiers in Molecular Biosciences | www.frontiersin.org 10 April 2017 | Volume 4 | Article 19
Castle and Gill Physiological Function of Prion Protein
were associated with reduced survival time from diagnosis (Sy
et al., 2011). PrPC expression was also shown to be upregulated in
cancerous tissue from human gastric cancer patients compared
with adjacent non-cancerous tissue from the same individuals
(Zhou et al., 2014), although a recent study of a larger patient
group found the opposite correlation (Tang et al., 2016).
Differentiation often involves a change in cell morphology,
such as neurite extension, and this will likely require altered
expression of cytoskeletal proteins. Several proteomic studies
have identified such changes in cell lines in which PrPC was
knocked down or overexpressed (Provansal et al., 2010; Weiss
et al., 2010; Mehrabian et al., 2014) and also in PrPC-null
liver tissues compared with wild type controls (Arora et al.,
2013). Analyses of brain tissues have been less successful at
detecting differential expression of cytoskeletal proteins (or of
any proteins for that matter), although this could be because cell
type-specific effects of PrPC are averaged out over an entire tissue
(Crecelius et al., 2008; Mehrabian et al., 2016). Another common
feature of differentiation is a change of cell cycle progression.
For example, neural precursors withdraw from the cell cycle
as they differentiate into post-mitotic neurons. In this regard,
PrPC has been shown to inhibit proliferation of oligodendrocyte
precursors (Bribian et al., 2012), neuronal cells (Kim et al., 2005)
and cells derived from the intestinal epithelium (Morel et al.,
2008). In the case of NSCs, one study found that expression
of full length PrPC promoted proliferation, whilst the N1 and
N2 fragments appeared to be inhibitory (Haigh and Collins,
2014). Interestingly, proliferation and self-renewal of NSCs and
their differentiation into neurons seem to rely, in part, upon
signalling mediated by ROS (Le Belle et al., 2011) and the effects
of the different N-terminal PrP fragments on NSC proliferation
apparently arose from their modulation of intracellular ROS
levels (Haigh and Collins, 2014). Therefore, regulation of NSC
proliferation by PrPC may be a consequence of its putative
antioxidant properties or, conversely, protection from oxidative
stress by PrPC may result from a role in regulating physiological
production of ROS for signalling purposes. PrPC has also been
observed to promote proliferation of colon adenocarcinoma cells
(Chieng and Say, 2015), neuroblastoma cells (Llorens et al.,
2013), cancer stem cells that give rise to glioblastoma (Corsaro
et al., 2016), and precursor cells in intestinal organoid cultures
(Besnier et al., 2015). In neuroblastoma cells, PrPC was proposed
to interact with the epidermal growth factor receptor to promote
activation of the PI3K-Akt pathway (Llorens et al., 2013). PI3K-
Akt-dependent mTOR activation might also drive the increased
protein synthesis required for differentiation processes, such as
changes to morphology (Roffe et al., 2010).
Although, PrPC-dependent regulation of neurite outgrowth,
cell adhesion, expression of cytoskeletal proteins and
proliferation could have been addressed separately, we argue
that these putative functions can be understood in the context
of PrPC modulating different types of cellular differentiation.
This explanation is attractive because, rather than affecting
various cellular processes via independent mechanisms, PrPC
may, instead, regulate the function of a single interacting partner
that underpins differentiation—given that altered regulation of
cell adhesion would have an impact on many differentiation
processes the interacting partner could be NCAM1, but there are
many other possibilities and further research will be required to
obtain a definitive answer.
Neuronal Excitability
As described in the previous section, interactions between
PrPC and mGLuRs have been linked to regulation of neurite
outgrowth (Beraldo et al., 2011). There are also reports
of PrPC interacting with other neurotransmitter receptors,
including α7 nicotinic acetylcholine (Beraldo et al., 2010),
kainate (Carulla et al., 2011), α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (Kleene et al., 2007), and N-methyl-
D-aspartate receptors (NMDARs) (Khosravani et al., 2008).
NMDARs are a subclass of ionotropic glutamate receptors
and are particularly implicated in excitotoxic neuronal cell
death, which occurs when overactivation of NMDARs causes
dysregulation of intracellular calcium homeostasis, leading to
disruption of various physiological processes (Bondy and Lee,
1993). NMDAR-mediated excitotoxicity contributes to neuronal
death in prion diseases and other neurodegenerative disorders
(Muller et al., 1993; Gorman, 2008). Intriguingly, PrPC has been
reported to inhibit activity of NMDARs containing the GluN2D
subunit, which suggests that PrPC may protect neurons from
excitotoxic death (Khosravani et al., 2008). There is evidence
for this in vivo, for example, Zurich I PrPC-knockout mice
displayed increased excitotoxicity in the retina in response
to damaging light intensities (Frigg et al., 2006) and in the
hippocampus following injection with N-methyl-D-aspartate
(Khosravani et al., 2008), which selectively activates NMDARs.
Given that excitotoxicity is the major cause of neuronal death
following ischaemic stroke (Lai et al., 2014), it is also interesting
to note that experimental stroke has been shown to induce
PrPC expression in the affected brain region in both rats and
mice (Weise et al., 2004; Shyu et al., 2005). Furthermore,
Zurich I PrPC-null mice displayed greater infarct volumes than
wild type controls after transient or permanent middle cerebral
artery occlusion (Spudich et al., 2005; Weise et al., 2006),
whilst injection of a PrPC-expressing adenovirus construct into
rat brains reduced infarct volume in a similar experimental
model (Shyu et al., 2005). In addition to potentially modulating
NMDAR activity, involvement of PrPC in the cellular response
to oxidative stress could explain the putative protective effect
of PrPC expression following stroke, since oxidative stress is a
feature of excitotoxicity.
Increased sensitivity to seizures induced by high-dose kainate
treatment has been observed in studies of Zurich I PrPC-
null mice (Rangel et al., 2009; Carulla et al., 2011). However,
this finding has been called into question by Striebel et al.
(2013b), who presented evidence that Prnp flanking genes may
be responsible for the seizure phenotype rather than Prnp
itself. Further adding to the complexity is a recent report
suggesting that, whilst Prnp flanking genes may affect sensitivity
to kainate treatment, PrPC expression also has a neuroprotective
effect (Carulla et al., 2015). Additionally, one study found
that hippocampal slices from Zurich I PrPC-null mice were
actually more resistant than wild type controls to three different
seizure-inducing protocols, including removal of Mg2+ from the
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culture medium, which leads to hyperexcitability of NMDARs,
and treatment with gamma-aminobutyric acid (GABA) receptor
antagonists (Ratte et al., 2011).
If PrPC can modulate neuronal excitability then one
might expect a lack of PrPC expression to affect synaptic
plasticity. Indeed, Collinge et al. (1994) showed that Zurich
I PrPC-knockout mice had disrupted hippocampal long-term
potentiation (LTP), a form of synaptic plasticity involved in
memory formation. These mice displayed abnormal behaviour
in nest building and novel environment exploration tasks and
more pronounced age-related decline in short-term memory
compared to wild type controls (Schmitz et al., 2014), effects
that are possibly underpinned by impaired LTP. Intriguingly, it
has been reported that the effect of ageing on memory can be
blocked by infusing wild type mice with a peptide containing
the putative PrPC-binding site of STI1 (Rial et al., 2009). Mice
overexpressing PrPC were similarly protected from age-related
memory decline in the same study. NMDAR activity is required
for LTP in the area of the hippocampus that was used by Collinge
et al. (1994), suggesting that the disrupted LTP observed by
the authors in PrPC-null hippocampal slices could have been
caused by PrPC ablation affecting NMDAR activity, as has been
described previously (Khosravani et al., 2008). However, Collinge
et al. (1994) found that the contribution of NMDAR-mediated
currents to excitatory postsynaptic potentials was unaffected by
PrPC knockout. Instead, the lack of PrPC expression resulted in
weaker fast inhibitory postsynaptic potentials generated through
GABA receptors. In contrast, a different study identified no
effects of PrPC knockout on inhibitory currents generated by
GABA receptors nor, indeed, on LTP itself (Lledo et al., 1996).
Together, the findings reported in this section paint a
confusing picture, indicating that further work is required to
determine conclusively how PrPC affects neuronal excitability.
There is increasing recognition of the contribution of Prnp
flanking genes to phenotypes displayed by PrPC-knockout mice
that were generated on mixed genetic backgrounds, an issue that
confounds interpretation of many studies connecting PrPC to the
regulation of neuronal excitability—this problem is documented
in more detail in a couple of recent review articles (Striebel
et al., 2013a; del Rio and Gavin, 2016). Nevertheless, there are
data from animal models other than mice that support the
involvement of PrPC in the modulation of neuronal excitability.
For example, knocking out PrP2 expression in zebrafish using
zinc finger nuclease technology affected NMDAR currents
and increased susceptibility to seizures induced by the drug
pentylenetetrazol (Fleisch et al., 2013). Furthermore, in a study
of the Drosophila neuromuscular junction, researchers found
that murine PrPC expression resulted in enlarged synaptic
vesicles and increased the probability of neurotransmitter release
(Robinson et al., 2014).
Myelin Maintenance
One phenotype of PrPC-knockout mice that was discovered
relatively recently is a widespread, adult-onset demyelination of
the PNS. This phenotype has now been observed in Zurich I and
Npu knockout mice (Bremer et al., 2010) as well as the newly
generated Zurich III line (Nuvolone et al., 2016), which provides
strong evidence that PrPC is involved in myelin maintenance.
Intriguingly, Bremer et al. (2010) showed that neuron-specific
PrPC expression was sufficient to rescue the demyelination
phenotype, whereas PrPC expressed only in Schwann cells
had little effect. More recent work has shown that PrPC may
promote myelin maintenance through an interaction between
its extreme N-terminal region (residues 23–33) and G-protein
coupled receptor 126 (GPR126) on the surface of Schwann cells
(Kuffer et al., 2016). There is some evidence that α-cleavage
of neuronal PrPC is needed to prevent PNS demyelination
(Bremer et al., 2010), perhaps indicating that the released N1
fragment, which contains the 23–33 region, is responsible for the
interaction with GPR126. Binding of the PrPC N-terminus seems
to promote receptor activation, initiating signalling through the
cyclic adenosine monophosphate (cAMP)-PKA pathway (Kuffer
et al., 2016). In zebrafish, PKA acting downstream of GPR126 was
shown to induce myelination during embryonic development
by upregulating expression of E3 SUMO-protein ligase EGR2
(Glenn and Talbot, 2013), a transcription factor that also seems
to regulate myelin maintenance (Decker et al., 2006). In spite
of the importance of the GPR126-PKA signalling axis in the
initial myelination of PNS axons, PrPC-null mice appear to
develop morphologically-normal myelin before onset of the
demyelinating polyneuropathy (Bremer et al., 2010). Kuffer et al.
(2016) suggested that developmental myelination may progress
normally in the PrPC-knockout mice because the lack of PrPC
expression is compensated for by other GPR126 ligands such as
type IV collagen and laminin-211, which have both been reported
to regulate GPR126 activity (Paavola et al., 2014; Petersen
et al., 2015). However, it has also been reported that GPR126-
PKA signalling is not required for myelin maintenance. For
example, E3 SUMO-protein ligase EGR2 expression by zebrafish
Schwann cells was shown to be independent of GPR126 signalling
following completion of initial myelination (Glenn and Talbot,
2013). Thus, the molecular mechanisms by which PrPC affects
myelin integrity are still to be determined conclusively.
No myelin-related abnormalities have been identified within
the CNS of PrPC-knockout mice (Bremer et al., 2010), perhaps
because CNS myelination reportedly does not depend upon
GPR126 activity (Monk et al., 2011). However, it is of note that
spinal cord expression of PrPC was found to be reduced in human
patients with multiple sclerosis, a demyelinating disease of the
CNS (Scalabrino et al., 2015).
Circadian Rhythm
The distinctive clinical feature of a human prion disease known
as fatal familial insomnia is severe disruption of the sleep-
wake cycle (Collins et al., 2001). Strikingly, PrPC-null mice also
exhibit alterations to their sleep structure, including faster cycling
through the different stages of sleep and more brief awakenings
than wild type mice (Tobler et al., 1996, 1997; Sanchez-Alavez
et al., 2007). These issues may be caused by changes to the
regulation of melatonin production—melatonin is synthesised
by the pineal gland and regulates sleep timing as well as other
processes. Melatonin production is under the control of the
suprachiasmatic nucleus of the hypothalamus, which is the
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master regulator of the circadian rhythms that drive the sleep-
wake cycle. Thus, melatonin levels vary according to a 24-h
cycle—for nocturnal animals such as mice, levels are highest in
the hours of darkness and lower levels are required for sleep
initiation. One study found that serummelatonin levels of Zurich
I and Npu PrPC-knockout mice were considerably lower than
in wild type mice during the dark phase of the cycle but were
higher during the light phase (Brown et al., 2002), which probably
contributed to the sleep disruption. A network of proteins called
the circadian clock work together to generate circadian rhythms
and, strikingly, PrnpmRNA levels seem to be subject to circadian
oscillations in the suprachiasmatic nucleus in addition to other
areas of the rat forebrain (Cagampang et al., 1999). Together,
these lines of evidence suggest that PrPC might have a regulatory
role in the sleep-wake cycle, raising the possibility that a loss
of this function is involved in the pathogenesis of fatal familial
insomnia.
Given that metabolic processes are also subject to circadian
regulation (Dibner et al., 2010), one might expect PrPC-knockout
mice to show signs of altered metabolism. Interestingly, recent
data suggest that PrPC knockout does have an effect on glucose
homeostasis. For example, Strom et al. (2011) demonstrated that,
compared with wild type controls, blood glucose levels of PrPC-
null mice were slower to return to normal after intraperitoneal
injection of glucose. In the same study, pancreatic insulin
secretion and the effects of intraperitoneal insulin injection on
blood glucose levels were shown to be similar irrespective of
PrPC expression, however, it has been reported that insulin
resistance develops more quickly in PrPC-null mice in response
to a high fat diet (Brito et al., 2013). More work is required
to unpick the mechanisms behind these phenotypes, although
evidence obtained in vitro suggests that PrPC-mediated Fyn
kinase signalling can lead to activation of hypoxia-inducible
factor-2α and subsequent upregulation of glucose transporter
1 expression, resulting in increased glucose uptake by cells (Li
et al., 2011). Additionally, glucose homeostasis is known to be
regulated by the PI3K-Akt pathway (Schultze et al., 2012), which
PrPC has also been reported to modulate (Vassallo et al., 2005;
Roffe et al., 2010; Llorens et al., 2013).
Metal Ion Homeostasis
A number of early studies of PrPC function focused on an
apparent ability to bind Cu2+ ions at the cell membrane through
the octapeptide repeat region (Hornshaw et al., 1995a,b; Brown
et al., 1997a). Subsequently, PrPC interactions with Cu2+ have
been implicated in the regulation of NMDAR activity (Gasperini
et al., 2015), astrocytic glutamate uptake (Brown and Mohn,
1999), protection against oxidative stress (Rachidi et al., 2003;
Watt et al., 2007) and maintenance of Cu2+ homeostasis in the
placenta (Alfaidy et al., 2013). In addition, binding of Cu2+ by
PrPC in the presence of ROS appears to promote β-cleavage of
PrPC, leading to production of C2 and N2 (McMahon et al.,
2001; Watt et al., 2005; McDonald et al., 2014). However, whilst
it is clear that PrPC can bind Cu2+ in vitro, the relevance
of this interaction in vivo has been questioned. For example,
it was reported that PrPC-dependent internalisation of Cu2+
by cells in culture occurred only when the extracellular Cu2+
concentration exceeded physiologically relevant levels (Rachidi
et al., 2003). Furthermore, although some studies have shown
that PrPC expression can protect neuronal and non-neuronal cell
lines from oxidative stress caused by excessive Cu2+ (Rachidi
et al., 2003; Watt et al., 2007), Cingaram et al. (2015) found that
transfecting PrPC into the Zpl hippocampal cell line, originally
derived from Zurich I PrPC-knockout mice, did not result in
protection from Cu2+-mediated toxicity.
Experiments in neuronal cell lines showed that PrPC
transfection did not confer protection against the oxidative DNA
damage and subsequent cell death caused by treatment with high
levels of Mn2+, Co2+, or Zn2+ (Watt et al., 2007; Cingaram et al.,
2015). However, PrPC expression did protect neuroblastoma cells
from the toxic effects of Fe2+ treatment (Watt et al., 2007).
Furthermore, PrPC appears to be involved in the physiological
uptake of iron by cells; this was first shown in neuroblastoma
cells, which became more efficient at sequestering iron from the
culture medium following overexpression of PrPC (Singh et al.,
2009b). Singh et al. (2009a) also showed that PrPC transfection
increased expression of the iron-storage protein ferritin and
reduced expression of both the iron-transport protein transferrin
and the transferrin receptor. These alterations to the expression
levels of iron-binding proteins are part of the homeostatic
response that ensures that the amount of labile iron within
cells remains constant when iron uptake is enhanced (Hare
et al., 2013). Further evidence supporting a role for PrPC in
iron homeostasis has been obtained in vivo, where the liver,
spleen, brain and kidneys of Zurich I PrPC-null mice have all
been shown to have lower total levels of iron than wild type
controls (Singh et al., 2009a; Haldar et al., 2015). Consequently,
PrPC-knockout also reduced ferritin expression and increased
expression of transferrin and its receptor in various tissues
(Singh et al., 2009a). Most iron circulating in the bloodstream
is in the form of Fe3+ bound to transferrin (Hare et al., 2013);
however, Fe3+ must be reduced to Fe2+ by a ferrireductase
to enable uptake by cells. PrPC itself may have ferrireductase
activity (Singh et al., 2013; Haldar et al., 2015) and may act to
enhance iron uptake through divalent-metal transporter 1 and
ZIP14 (Tripathi et al., 2015), although an alternative explanation
is that PrPC binds through its octapeptide repeat region to a
ferrireductase in order to modulate its activity (Tripathi et al.,
2015). One final point to make is that PrPC-null mice are
only mildly anaemic, probably because, in spite of the low
levels of stored iron, sufficient quantities of labile iron were
present to maintain normal cellular function (Singh et al.,
2009a).
In conclusion, more than two decades after the discovery
that PrPC can bind Cu2+, the functional significance of this
interaction is still unclear. However, the recent reports proposing
that PrPC is involved in iron homeostasis are intriguing. Further
research is necessary to clarify themechanisms responsible and to
determine whether other PrPC-knockoutmouse lines also display
signs of anaemia.
Roles in the Immune System
Because prion diseases are neurodegenerative disorders, much
of the research into PrPC function has focused on its role
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in the nervous system. However, PrPC is also expressed in
immune cells, including T-lymphocytes, natural killer cells,
macrophages and mast cells (Durig et al., 2000; Haddon
et al., 2009). Mast cells reportedly express high levels of PrPC,
some of which is shed from the cell membrane as the N3
fragment (Haddon et al., 2009). When activated, mast cells
release various inflammatory mediators, including histamine,
prostaglandins and cytokines (Stempelj and Ferjan, 2005).
Interestingly, treatment of cultured mast cells with compounds
that induce activation resulted in rapid shedding of a large
proportion of the cellular pool of PrPC, suggesting that PrPC
could be involved in the inflammatory response (Haddon et al.,
2009). Mast cells are also involved in angiogenesis (Maltby
et al., 2009), a process that PrPC seems to modulate within
the placenta (Alfaidy et al., 2013), although this function
may be more linked to the putative antioxidant properties
of PrPC. Moreover, mast cells release pain mediators upon
activation (Chatterjea and Martinov, 2015) and ablation of PrPC
expression in mice is associated with altered sensitivity to pain.
However, whilst one study found that PrPC-null mice showed a
hypersensitivity to pain (Gadotti and Zamponi, 2011), another
demonstrated that PrPC-null mice were more resistant than
wild type controls (Meotti et al., 2007). It is conceivable that
the apparent influence of PrPC expression on pain sensitivity
stems from a role in regulating mast cell function, although
Gadotti and Zamponi (2011) provided evidence that loss of
PrPC-dependent NMDAR inhibition was responsible for the
hypersensitivity to pain displayed by the PrPC-knockout mice in
their study.
PrPC expression by T-cells may be involved in their
differentiation, since knockdown of PrPC resulted in an increased
tendency for T-cells to develop a pro-inflammatory phenotype
(Hu et al., 2010). Additionally, in a model of autoimmune
encephalomyelitis, PrPC-knockout mice experienced a more
severe disease phenotype that was linked to increased T-cell-
dependent neuroinflammation (Tsutsui et al., 2008), possibly
because PrPC is involved in the signalling complexes that
regulate T-cell activation (Mabbott et al., 1997; Mattei et al.,
2004). In contrast, another study employing the autoimmune
encephalomyelitis model reported no evidence that T-cells
were driven toward a more inflammatory phenotype by PrPC
knockout and, instead, the increased disease severity seemed to
result from loss of PrPC expression within the CNS, not the
immune system (Gourdain et al., 2012).
As explained previously, the first non-laboratory animals
lacking PrPC expression were recently identified (Benestad et al.,
2012). No overt abnormalities were detected in these PrPC-
null goats (Benestad et al., 2012), although increased neutrophil
numbers compared with PrPC-expressing controls were reported
recently (Reiten et al., 2015). Further study of these PrPC-
null goats may help to improve understanding of how PrPC
expression influences the immune system, knowledge that is
currently rather limited. Of particular interest is the putative
function of PrPC expression in mast cells, given the multiple lines
of circumstantial evidence, detailed in this section, that hint at an
important role for PrPC in these cells.
Mitochondrial Homeostasis
Another function sometimes ascribed to PrPC is maintenance of
mitochondrial homeostasis. For instance, whilst mouse studies
have shown that PrPC-knockout does not affect the membrane
potential or baseline respiration rate of mitochondria, nor the
activities of the individual complexes of the electron transport
chain (Brown et al., 2002; Miele et al., 2002; Lobao-Soares et al.,
2005), transcriptomic, and proteomic analyses of brain tissue
and cultured cells have identified specific subunits of each of
the five electron transport chain complexes that vary in their
expression between PrPC-null and wild type mice (Miele et al.,
2002; Ramljak et al., 2008; Stella et al., 2012). Furthermore, the
Npu line of PrPC-null mice were found to have reduced numbers
of mitochondria in the brain and myocardium, although the
mitochondria that were present were larger and had increased
maximal respiratory capacities, presumably to compensate for
the lower numbers (Miele et al., 2002; Paterson et al., 2008).
The enhanced maximal respiratory capacity of individual PrPC-
null mitochondria seemed to be enabled by increased activity of
electron transport chain complex I, which was, in turn, associated
with an increase in superoxide production (Paterson et al., 2008).
In line with these findings, superoxide dismutase 2, which is
found within mitochondria and converts superoxide into either
hydrogen peroxide or molecular oxygen, was reportedly more
active in PrPC-null mice (Brown et al., 1997b; Miele et al.,
2002; Paterson et al., 2008). Furthermore, it is conceivable
that the reported antioxidant properties of PrPC could derive
from a role in maintaining mitochondrial homeostasis and,
consequently, preventing excessive production of ROS. It should
be emphasised, however, that the evidence suggesting that PrPC
may regulate mitochondrial function comes from a very limited
number of studies and, as far as we aware, the only published
examples of mitochondrial phenotypes in PrPC-null mice are
from studies of the Npu line.
Roles in Regulating Levels of Amyloid Beta
and Tau
β-Cleavage of the amyloid precursor protein (APP) by beta-
secretase 1 produces a fragment called sAPPβ that is subsequently
cleaved by gamma-secretase to produce amyloid beta (Aβ)
peptides. Aβ accumulates during pathogenesis of Alzheimer’s
disease (AD) and PrPC reportedly acts as an inhibitor of β-
secretase 1 (Parkin et al., 2007; Whitehouse et al., 2013),
thereby reducing the amount of Aβ produced and suggesting
that PrPC expression should protect against the development
of AD. A feedback loop has also been proposed that consists
of the APP intracellular domain (the other fragment produced
by cleavage of sAPPβ) activating cellular tumour antigen p53,
which subsequently upregulates PrPC expression, leading to
further inhibition of β-secretase 1 activity (Vincent et al.,
2009). However, recent data have questioned whether the APP
intracellular domain is able to induce PrPC expression (Lewis
et al., 2012), whilst another study found that PrPC expression
actually led to higher rates of APP β-cleavage (McHugh et al.,
2012). In addition, removing PrPC from human APP-expressing
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mice has no effect on processing or Aβ levels (Whitehouse et al.,
2016).
In addition to potentially affecting APP processing, it has been
suggested that PrPC downregulates transcription of microtubule-
associated protein tau by activating Fyn kinase signalling
(Chen et al., 2013). This putative function would also be
protective against AD, since accumulation of neurofibrillary
tangles consisting of hyperphosphorylated tau is another major
molecular feature of the disease. Conversely, oligomeric forms
of Aβ are reported to bind to PrPC at either its extreme N-
terminal region (Chen et al., 2010; Dohler et al., 2014) or between
residues 92 and 110 (Lauren et al., 2009), potentially eliciting
toxic effects through hyperactivation of Fyn kinase (Vergara
et al., 2015). The C1 fragment, created by α-cleavage of PrPC,
lacks both the putative Aβ binding sites. Therefore, the reduced
levels of hippocampal PrPC and the increased rates of PrPC α-
cleavage in the cortex that have been reported in the brains
of sporadic AD patients could be part of a protective response
(Whitehouse et al., 2010; Beland et al., 2014). On the other
hand, one study found that higher levels of PrPC in serum were
correlated with poorer cognitive function in an elderly human
population, although the increase in serum PrPC could be a
consequence of loss of PrPC from neuronal membranes (Breitling
et al., 2012). Overall, the conflicting nature of the evidence
obtained to date makes it difficult to determine whether the
net effect of PrPC expression on AD pathogenesis is positive or
negative.
Interacting Partners of PrPC
The preceding sections of this review have addressed many
of the diverse functions ascribed to PrPC. Putative interacting
partners of PrPC that may be involved in these functions have
also been mentioned and Table 2 provides information about
some of the interactions best supported by the literature. Given
that the GPI-anchored PrPC molecule lacks an intracellular
domain, it is likely that the protein interacts with one or
more co-receptors at the cell surface to mediate downstream
signalling. Several potential co-receptors are included in Table 2,
such as NCAM1 and mGluRs, which may be involved in
PrPC-dependent neurite outgrowth (Santuccione et al., 2005;
Beraldo et al., 2011). Furthermore, the extracellular matrix
protein laminin may act as a PrPC ligand (Graner et al.,
2000a) to activate neuritogenic signalling downstream ofmGluRs
(Beraldo et al., 2011). Likewise, STI1 released by astrocytes (Lima
et al., 2007) may form a complex with nicotinic acetylcholine
receptors and PrPC on the neuronal surface, leading to activation
of the acetylcholine receptors and consequent pro-survival
and neuritogenic signalling (Beraldo et al., 2010). Interactions
between PrPC and neurotransmitter receptors are also implicated
in the regulation of neuronal excitability, although some of these
findings have been disputed, as explained previously. Further
PrPC binding partners listed in Table 2 include proteins that
are important at cell-cell junctions, such as desmoplakin and
junction plakoglobin (Zafar et al., 2011; Besnier et al., 2015),
and may be linked to the role PrPC is thought to play in the
regulation of cell adhesion (Malaga-Trillo et al., 2009; Sempou
et al., 2016). Additionally, PrPC reportedly binds to cytoskeletal
proteins, such as tubulin and vimentin (Nieznanski et al., 2005;
Zafar et al., 2011), although, given that PrPC is usually expressed
at the cell surface, these findings could be artefactual. For
example, cell or tissue lysis carried out prior to analysis of
protein-protein interactions can result in association of proteins
that do not interact physiologically because of their differing
subcellular localisation. An alternative explanation is that PrPC
does interact with cytoskeletal proteins but does so indirectly—
not all techniques used to identify binding partners of a
protein can distinguish between direct and indirect interactions.
Desmoplakin, for example, could provide the link between
PrPC and tubulin or vimentin, since desmoplakin is reported
to interact with the microtubule-binding protein end-binding
1 (Patel et al., 2014) and with vimentin intermediate filaments
(Stappenbeck and Green, 1992). In fact, many of the proteins
that appear to interact with PrPC may merely be part of the
samemultiprotein complex or complexes rather than being direct
binding partners. Alternatively, the relatively flexible structure
of the PrPC N-terminal domain may allow the protein to bind
directly to multiple partners (Bakkebo et al., 2015), potentially
enabling PrPC to act as a scaffolding protein that mediates the
formation of a number of different multiprotein complexes at
the cell surface, as has been proposed previously (Linden et al.,
2008).
Signalling Pathways Affected by PrPC
Expression
Interactions between PrPC and its co-receptor(s) initiate
downstream signalling and Figure 5 provides an overview of the
signalling pathways that seem to be affected by PrPC expression
as well as some of the cellular processes that may be regulated
in a PrPC-dependent manner through these pathways. Further
information on these signal transduction pathways was retrieved
from several review articles (Dhillon et al., 2007; Newton,
2010; Rosse et al., 2010; Zhang and Yu, 2012; Martini et al.,
2014), enabling some of the crosstalk between pathways to be
included in the figure. In brief, evidence suggests that PrPC
expression affects the activities of the ERK1/2 (Lopes et al.,
2005; Caetano et al., 2008; Beraldo et al., 2011) and PI3K-Akt
signalling pathways (Vassallo et al., 2005; Roffe et al., 2010;
Llorens et al., 2013), both of which are involved in functions
ascribed to PrPC such as regulation of protein synthesis (Roffe
et al., 2010) and autophagy (Nah et al., 2013; Shin et al., 2014).
In addition, differential activation of the PI3K-Akt pathway may
explain the effects of PrPC expression on proliferation (Llorens
et al., 2013). Furthermore, PrPC appears to modulate cAMP-
PKA signalling to stimulate the maintenance of PNS myelin
(Kuffer et al., 2016) and to promote cell survival (Lopes et al.,
2005), although it should be stressed that the literature as a
whole does not provide strong support for PrPC having a direct
pro-survival role, as explained previously. PrPC expression also
seems to activate signalling through Src family kinases, such
as Fyn kinase (Krebs et al., 2007; Chen et al., 2013), leading
to changes in cell adhesion properties (Sempou et al., 2016)
as well as potentially affecting the cellular uptake of glucose
(Li et al., 2011), a process that can additionally be regulated
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TABLE 2 | Reported interacting partners of PrPC.
Protein/protein complex Subcellular localisation and function Method References
14-3-3 protein Cytoplasmic adaptor protein involved in multiple
signalling pathways
Interactomics; co-IP Satoh et al., 2005; Zafar et al., 2011
37/67 kDa laminin receptor Cell surface receptor for laminin (see below) Binding assay; yeast
two-hybrid; co-IP
Gauczynski et al., 2001; Hundt et al., 2001
60 kDa heat shock protein Mitochondrial chaperone Interactomics; co-IP Satoh et al., 2005; Zafar et al., 2011
Annexin A2 Calcium-regulated cell membrane protein with a
poorly defined function
Interactomics; co-IP Morel et al., 2008; Zafar et al., 2011
Desmoplakin Organisation of cell junctions Interactomics; co-IP Morel et al., 2008; Besnier et al., 2015
Dipeptidyl aminopeptidase-like
protein 6
Cell membrane protein that binds to and modulates
activity of potassium channels
Interactomics; co-IP Schmitt-Ulms et al., 2004; Mercer et al., 2013
Doppel Cell membrane protein of unknown function Co-IP Qin et al., 2006; Caputo et al., 2010
Junction plakoglobin (a.k.a.
γ-catenin)
Organisation of cell junctions Interactomics; yeast
two-hybrid
Besnier et al., 2015; Lappas Gimenez et al., 2015
Laminin Extracellular matrix protein with multiple functions
(cell migration, adhesion, differentiation...)
Binding assay Graner et al., 2000a; Coitinho et al., 2006
Lactate dehydrogenase Cytoplasmic enzyme that converts lactate to
pyruvate and vice versa
Interactomics; co-IP Zafar et al., 2011; Ramljak et al., 2015
Metabotropic glutamate receptor Cell surface receptor for the neurotransmitter
glutamate
Co-IP; binding assay Beraldo et al., 2011; Haas et al., 2014
Neural cell adhesion molecule 1 Cell membrane protein with multiple functions
(adhesion, neurite outgrowth...)
Co-IP; binding assay Schmitt-Ulms et al., 2001; Santuccione et al.,
2005
Nicotinic acetylcholine receptor Cell surface receptor for the neurotransmitter
acetylcholine
Co-IP; binding assay Petrakis et al., 2008; Beraldo et al., 2010
Stress-induced phosphoprotein 1 Cytoplasmic co-chaperone; may also be secreted
to function as a PrPC ligand
Binding assay; co-IP Zanata et al., 2002; Lopes et al., 2005
Tubulin Cytoskeletal protein (microtubules) Interactomics; co-IP Nieznanski et al., 2005; Zafar et al., 2011
Vimentin Cytoskeletal protein (intermediate filaments) Interactomics; yeast
two-hybrid
Zafar et al., 2011; Lappas Gimenez et al., 2015
Some of the proteins that may interact with PrPC. Numerous interacting partners have been suggested but we include only those proteins for which two separate references could
be found that provided direct evidence of an interaction with PrPC. This is not meant to indicate that interactions identified in a single reference are incorrect, especially in the case of
recently identified interactions. It is also important to state that certain techniques, such as co-immunoprecipitation (co-IP), do not distinguish between indirect and direct interactions.
Therefore, some of the proteins listed in this table may interact with PrPC indirectly.
by the PI3K-Akt pathway (Schultze et al., 2012). Finally, PrPC-
dependent regulation of several pathways, including RhoA-
ROCK (Loubet et al., 2012) and PKC (Beraldo et al., 2011)
signalling, reportedly results in changes to cell morphology, such
as neuritogenesis.
The extensive nature of the crosstalk between pathways
affected by PrPC expression raises the possibility that they
may not all be regulated by PrPC directly; instead, the altered
activation states of some of the pathways may be indirect
consequences of effects on other signalling cascades. Moreover,
although PrPC expression has an activating effect on most
of the pathways shown in Figure 5, it is highly unlikely
that this is the case for all tissue/cell types. For example,
the PI3K-Akt pathway is thought to promote proliferation
(Martini et al., 2014) and yet PrPC expression has been
shown to have opposing effects on proliferation in different
experimental models. Context-dependent regulation of cell
signalling processes by PrPC could result from co-receptors
and/or downstream components of the relevant signalling
pathways being differentially expressed in different tissue/cell
types.
FINAL CONCLUSIONS AND FUTURE
PERSPECTIVES
Since it was first recognised that prion protein misfolding
plays an important role in the pathogenesis of prion diseases,
significant attention has been directed toward understanding the
physiological function of PrPC. One goal of such research has
been to determine whether the disease processes of prion diseases
are driven mainly by toxic gain of function caused by conversion
of PrPC into PrPSc or by a loss of normal PrPC function.
However, this question has yet to be answered conclusively,
because a clear description of PrPC function remains elusive.
This is not to say that no progress has been made; in fact,
PrPC has been linked to roles in a wide variety of cellular
processes. Furthermore, numerous putative interacting partners
of PrPC have been identified and PrPC expression has been shown
to affect a number of downstream signalling pathways. These
findings have led to proposals that PrPC is a scaffolding protein
that regulates the formation of various multiprotein complexes
at the cell surface. However, given the potential for experimental
artefacts when studying protein-protein interactions in addition
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FIGURE 5 | Signalling pathways regulated by PrPC. Various downstream signalling pathways are reportedly modulated as a result of PrPC interacting with
specific co-receptors (some candidate co-receptors are included in Table 2). Cellular functions regulated by these pathways are shown in italics. Arrows indicate
positive regulation, inhibition is shown by the flat-ended lines, and connectors without arrows indicate that the direction of regulation may be context-specific. Dotted
lines represent crosstalk between pathways; therefore, some of the pathways shown may be regulated indirectly through other pathways rather than modulated
directly by PrPC. SFK, Src family kinase, which includes Fyn kinase.
to the possible detection of indirect rather than direct PrPC
binding partners, the actual number of direct PrPC interactors
may be considerably lower than it appears. It is also possible
that some of the signalling processes reportedly affected by
PrPC expression are differentially activated due to crosstalk
with other pathways rather than as a result of direct regulation
by PrPC. Further adding to the complexity of understanding
PrPC function is recent evidence that has weakened support
for the involvement of PrPC in processes such as stress-
protection, copper homeostasis and the modulation of neuronal
excitability.
Arguably, the best-supported phenotype of PrPC-knockout
mice is adult-onset demyelination of the PNS, suggesting
that PrPC expression is important for myelin maintenance.
Additionally, there is accumulating evidence that PrPC
expression modulates proliferation, differentiation, adhesion
properties and cell shape in multiple cell types. Given that
proliferation rate, adhesion properties and cell shape are all likely
to be affected when cells differentiate, we have suggested in this
review that PrPC may regulate a single underlying mechanism
connected to differentiation and further work will be required
to determine whether or not this is the case. Another intriguing
phenotype of PrPC-null mice is altered sleep structure, which
may result from disruption of the normal circadian variation
in melatonin levels. However, there have been few publications
on this topic, which is surprising since a role of PrPC in sleep
regulation would suggest that loss or subversion of normal
PrPC function could be involved in the development of fatal
familial insomnia. Other areas of study that could be explored
further include the link between PrPC and iron homeostasis as
well as the putative involvement of PrPC in immune function,
especially in the context of mast cells, which reportedly shed
large quantities of the N3 fragment from the cell surface when
activated.
Aside from the involvement of prion protein in prion
diseases, there are wider reasons for pursuing investigations
to clarify the function of PrPC. Firstly, given that PrPC has
been shown to affect processes such as proliferation, cellular
differentiation and adhesion, the expression levels of PrPC are
likely to have an influence on cancer progression. Although,
some attention has been focused on this topic in recent years,
further research would help to determine whether treatments
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that modulate PrPC activity or expression levels are beneficial
in cancer. Secondly, the putative connection between PrPC and
glucose homeostasis makes the protein a potential target for
treating metabolic disorders such as diabetes. Thirdly, given that
dementia is one of the most pressing medical issues of our time,
the apparent role of PrPC in the cell biology of AD warrants
further attention, especially since the relevant data obtained
to date are rather contradictory. Together, these areas provide
further impetus for continued research into the cell biological
mechanisms regulated by PrPC, raising the possibility that a clear
understanding of PrPC function will be obtained in the near
future.
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